Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment
Authors:
- 1 October 2016
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 83, 1428-1435
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assemblyBiomaterials, 2012
- Conjugation of paclitaxel on adeno-associated virus (AAV) nanoparticles for co-delivery of genes and drugsEuropean Journal of Pharmaceutical Sciences, 2012
- Mannosylated liposomes for targeted gene deliveryInternational Journal of Nanomedicine, 2012
- Assessing cytotoxicity of boron nitride nanotubes: Interference with the MTT assayBiochemical and Biophysical Research Communications, 2010
- Novel cationic SLN containing a synthesized single-tailed lipid as a modifier for gene deliveryNanotechnology, 2009
- Lipid nanoparticles for parenteral delivery of activesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targetingJournal of Microencapsulation, 2008
- Cytoskeleton dynamics: Fluctuations within the networkBiochemical and Biophysical Research Communications, 2007
- pH-sensitive liposomes are efficient carriers for endoplasmic reticulum-targeted drugs in mouse melanoma cellsBiochemical and Biophysical Research Communications, 2002
- An essential role for a phospholipid transfer protein in yeast Golgi functionNature, 1990